排序方式: 共有35条查询结果,搜索用时 31 毫秒
1.
The protected ceramide: N‐((2S,3S,4R)‐3,4‐bis(benzyloxy)‐1‐hydroxyoctadecan‐2‐yl)tetracosanamide, was attempted to introduce a triflate as a leaving group followed by a nucleophilic substitution with azido group in one‐pot manner. Unexpectedly, the oxazole ring formed via a thermodynamically favored intramolecular cyclization was opened to generate the original ceramide by triflic acid. In addition, the residual acid promoted a formylation of the primary hydroxy group in DMF. 相似文献
2.
3.
4.
The quantum field theory of stimulated Raman scattering is formulated. It is shown to give the correct classical limit. Ilowever, the quantum growth rate is bigger. An additional physical process of creation of two plasmons from two photons is intrinsically predicted by the theory. 相似文献
5.
In this report,the stable corona discharge region of multi-wire proportional cham-ber(MWPC)has been measured.In this region we observed double peak pheno- menon in Fe55 pulse amplitude distribution,and establish the fact that,once cornadischarge region is present in MWPC,the spatial resolution power for light partic-les will be lost. 相似文献
6.
ZHAO ZHEN-LAN XU YUAN-BIAO GUO YING-HUAN LO SHI-HUA HUANG ZHONG-WIANG YANG RUI-YING 《中国物理C(英文版)》1982,6(1):111-112
In present paper, a non-classical method of obtaining the decay constant andhalf-life of 99mTc was introduced. The results were compared with that obtained bythe classical method of the least square analysis. The half-life by non-classioal me-thod is 6.006±0.004 hours, that by classical method is 6.009±0.005 hours. 相似文献
7.
无损残余应力测量及其新技术 总被引:1,自引:0,他引:1
简述及比较了主要的残余应力无损测量技术,重点为磁力法,并介绍一台新的磁力仪MAPS,且对MAPS及传统磁力仪作了比较,同时以X射线及中子衍射得到的结果验证了MAPS的可靠性,也介绍了文献上较少见的火车钢轨残余应力分布图。 相似文献
8.
9.
Peptides based on the amino acid sequences found at protein-protein interaction sites make excellent leads for antagonist development. A statistical picture of amino acids involved in protein-protein interactions indicates that proteins recognize and interact with one another through the restricted set of specialized interface amino acid residues, Pro, Ile, Tyr, Trp, Asp and Arg. These amino acids represent residues from each of the three classes of amino acids, hydrophobic, aromatic and charged, with one anionic and one cationic residue at neutral pH. The use of peptides as drug leads has been successfully used to search for antagonists of cell-surface receptors. Peptide, peptidomimetic, and non-peptide organic inhibitors of a class of cell surface receptors, the integrins, currently serve as therapeutic and diagnostic imaging agents. In this review, we discuss the structural features of protein-protein interactions as well as the design of peptides, peptidomimetics, and small organic molecules for the inhibition of protein-protein interactions. Information gained from studying inhibitors of integrin functions is now being applied to the design and testing of inhibitors of other protein-protein interactions. Most drug development progress in the past several decades has been made using the enzyme binding-pocket model of drug targets. Small molecules are designed to fit into the substrate-binding pockets of proteins based on a lock-and-key, induced-fit, or conformational ensemble model of the protein binding site. Traditionally, enzymes have been used as therapeutic drug targets because it was easier to develop rapid, sensitive screening assays, and to find low molecular weight inhibitors that blocked the active site. However, for proteins which interact with other proteins, rather than with small substrate molecules, the lack of binding pockets means that this approach will not generally succeed. There exist many diseases in which the inhibition of protein-protein interactions would provide therapeutic benefit, but there are no general methods available to address such problems. The focus of the first part of this review is to discuss the features of protein-protein interactions which may serve as general guidelines for the development and design of inhibitors for protein-protein interactions. In the second part we focus on the design of peptides (lead compounds) and their conversion into peptidomimetics or small organic molecules for the inhibition of protein-protein interactions. We draw examples from the important and emerging area of integrin-based cell adhesion and show how the principles of protein-protein interactions are followed in the discovery, optimization and usage of specific protein interface peptides as drug leads. 相似文献
10.